Genentech, Roche’s US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the Lausanne-based biotech.
After the EU Parliament’s Agriculture (AGRI) Committee called for a patent ban on NGT-1 breeds on 8 January, the ENVI Committee will give its input to the EU Commissions draft law on new genomic techniques.
AMSilk GmbH and Danish 21st.BIO A/S announce partnership to accelerate the production of advanced materials made from spider silk-based proteins.
Sleep diagnostics specialist Onera Health NV has closed a €30m (US$32m) Series C financing round co-led by EQT Life Sciences and Gimv.
Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.
Microbial production specialist Enifer has secured a €12m grant from Business Finland to build a mycoprotein ingredient factory with a capacity of 300,000 tonnes annually.
Italian mycelium specialist Mogu Srl has closed a €11m Series A financing co-led by CDP Venture Capital and the European Circular Bioeconomy Fund (ECBF VC)
Novo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections.
Calypso Biotech BV has entered into an agreement to be acquired by Novartis AG, which will pay. Calypso’s US$250m upfront upon closing plus of up to US$175.
Following in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.